

**CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE
MEETING ROSTER**

APRIL 25, 2006

Cellegesic™ (nitroglycerin ointment) 0.4%

NDA 21-359

Voting Committee Members:

David L. DeMets, Ph.D.
Steven D. Findlay, M.P.H.
John M. Flack, M.D., M.P.H.
Robert A. Harrington, M.D., F.A.C.C.
William R. Hiatt, M.D.
Frederick J. Kaskel, M.D., Ph.D.
Michael A. Lincoff, M.D.
Thomas G. Pickering, M.D., D.Phil.
Ronald J. Portman, M.D.
John R. Teerlink, M.D.
Lynn Warner-Stevenson, M.D.

Temporary Voting Members (Special Government Employee Consultants):

Walter A. Koltun, M.D.

Non-Voting Participants:

George S. Goldstein, M.D. (Industry Representative)

Non-Voting FDA Participants:

Robert J. Temple, M.D.
Norman L. Stockbridge, M.D., Ph.D.

**FOOD AND DRUG
ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)**

*Cardiovascular and Renal Drugs Advisory Committee
Meeting
April 25, 2006
Participant List*

Voting Participant:

Special Government Employee Consultants

Walter A. Koltun, M.D., F.A.C.S., F.S.C.R.S.
Chief, Colon and Rectal Surgery
Peter and Marshia Carlino Professor in Inflammatory Bowel Disease
Penn State Milton S. Hershey Medical Center
500 University Drive
Hershey, PA 17033

Non-Voting Participants:

George S. Goldstein, M.D., F.A.A.P (Industry Representative)
Corp. VP Worldwide Medical and Regulatory Affairs
Sterling Drug Inc. (Retired)
Pharmaceutical Consultant to CHPA
6 Pebble Beach Lane
White Plain, New York 10605

FDA Participants

Norman Stockbridge, M.D.
Director
Division of Cardiovascular and Renal Drug
Products
FDA/CDER

Robert Temple, M.D.
Director
Office of Drug Evaluation I (ODEI)
FDA/CDER